Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of BST02 Injection in Advanced Liver Cancer
NCT06173726Phase 1Not yet recruiting
- Sponsor
- Biosyngen
- Start
- Dec 2023
- Primary completion
- Dec 2026
- Modality
- Tumor-Infiltrating Lymphocytes (TILs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BST02 in liver cancer, hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA), sponsored by Biosyngen. Primary endpoints: Adverse Event, Severe Adverse Event and 1 more. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
BST02
03
Conditions
liver cancerhepatocellular carcinoma (HCC)cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT06173726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06173726.